Pfizer Inc. $PFE Shares Bought by Integrated Investment Consultants LLC

Integrated Investment Consultants LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 102.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 51,012 shares of the biopharmaceutical company’s stock after acquiring an additional 25,861 shares during the period. Integrated Investment Consultants LLC’s holdings in Pfizer were worth $1,270,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Y Intercept Hong Kong Ltd acquired a new stake in shares of Pfizer during the 3rd quarter valued at approximately $3,019,000. Kepler Cheuvreux Suisse SA acquired a new stake in shares of Pfizer during the 3rd quarter valued at approximately $16,613,000. Money Concepts Capital Corp raised its position in shares of Pfizer by 29.9% during the 3rd quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock valued at $6,325,000 after acquiring an additional 57,188 shares in the last quarter. Penn Davis Mcfarland Inc. raised its position in shares of Pfizer by 50.9% during the 4th quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock valued at $4,266,000 after acquiring an additional 57,777 shares in the last quarter. Finally, Mackenzie Financial Corp raised its position in shares of Pfizer by 119.6% during the 3rd quarter. Mackenzie Financial Corp now owns 3,106,644 shares of the biopharmaceutical company’s stock valued at $79,157,000 after acquiring an additional 1,691,773 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced a Europe label expansion for its hemophilia therapy Hympavzi, which could broaden the drug’s commercial opportunity and support long-term revenue growth.
• Positive Sentiment: Multiple updates highlighted ongoing clinical and development activity, including a new Korea migraine study for Nurtec ODT, a Phase 1 food-effect study for PF-07799933, a prazosin site-transfer trial, and a planned Japan RSV vaccine trial. These reinforce Pfizer’s pipeline and global expansion efforts.
• Positive Sentiment: Recent commentary around Pfizer’s Q1 earnings pointed to improving momentum in new and acquired products, especially oncology and migraine treatments, as well as progress from the Seagen integration and legal settlements that may improve clarity around future cash flow.
• Neutral Sentiment: Media coverage also noted that investor sentiment remains mixed, with some analysts and commentators arguing Pfizer still lacks strong earnings momentum and is being supported more by its dividend and defensive valuation than by a clear near-term growth catalyst.
• Negative Sentiment: Pfizer continues to face concerns about declining COVID-related sales and looming patent expirations, which have weighed on the stock even after earnings beat expectations.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on PFE shares. CICC Research started coverage on Pfizer in a research report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price target on the stock. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Wednesday, February 4th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Guggenheim upped their price objective on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Finally, Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a research note on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus target price of $28.84.

Pfizer Trading Down 0.1%

NYSE:PFE opened at $25.31 on Monday. Pfizer Inc. has a 1 year low of $22.45 and a 1 year high of $28.75. The stock has a market cap of $144.25 billion, a price-to-earnings ratio of 19.32 and a beta of 0.35. The business has a fifty day moving average of $26.98 and a 200-day moving average of $26.20. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter in the prior year, the business posted $0.92 earnings per share. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. Pfizer’s dividend payout ratio is presently 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.